

## **2022 Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B**

### **Module 2A: Lymphoma, Acute Leukemia, Cancer-related Infectious Diseases, Hematopoietic Stem Cell Transplantation**

#### **Volume 2**

#### **Articles and Learning Objectives**

#### **Oncology Home Study Syllabus Module 2A: Lymphoma, Acute Leukemia, Cancer-related Infectious Diseases, Hematopoietic Stem Cell Transplantation 0204-9999-22-954-H01-P**

##### **Lymphoma**

###### **Article:**

Tilly H, Morschhauser F, Sehn LH et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med.* 2022;386:351-363.

###### **Learning Objectives:**

- Describe the POLARIX study of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for the first-line treatment of diffuse large B-cell lymphoma.
- Develop recommendations for the use of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for the first-line treatment of diffuse large B-cell lymphoma.

##### **Acute Leukemia**

###### **Article:**

Wei AH, Döhner H, Pocock C et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. *N Engl J Med.* 2020;383(26):2526-2537.

###### **Learning Objectives:**

- Analyze the efficacy and safety data for the use of oral azacitidine maintenance to treat patients with acute myeloid leukemia.
- Select appropriate supportive care and monitoring strategies for patients treated with oral azacitidine.
- Choose appropriate therapy for patients with acute myeloid leukemia based on the results of the QUAZAR AML-001 trial.

## **Hematopoietic Stem Cell Transplantation**

Article:

Watkins B, Qayed M, McCracken C et al. Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. *J Clin Oncol*. 2021;39:1865-1877.

Learning Objectives:

- Describe the study of abatacept for acute graft-versus-host disease (GVHD) prevention in allogeneic hematopoietic cell transplant.
- Develop recommendations for the use of abatacept in allogeneic hematopoietic cell transplant for prevention of acute GVHD.
- Evaluate study design for treatment regimens for prevention of GVHD.

## **Cancer-related Infectious Diseases**

Article:

Johnson S, Lavergne V, Skinner AM et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of *Clostridioides difficile* infection in adults. *Clin Infect Dis*. 2021;73:e1029-e1044.

Learning Objectives:

- Describe the 2021 focused update of the clinical practice guideline from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for the management of *Clostridioides difficile* infection in adults.
- Develop recommendations for the management of initial and recurrent *Clostridioides difficile* infection episodes in adults.
- Select appropriate patients to receive bezlotoxumab based on the IDSA/SHEA guidelines.

## **2022 Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 2A-B**

### **Module 2B: Breast Cancer, Colon Cancer, Lung Cancer, Prostate Cancer**

#### **Volume 2**

#### **Articles and Learning Objectives**

#### **Oncology Home Study Syllabus Module 2B: Breast Cancer, Colon Cancer, Lung Cancer, Prostate Cancer**

**0204-9999-22-955-H01-P**

#### **Prostate Cancer**

Article:

Virgo KS, Rumble RB, de Wit R et al. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. *J Clin Oncol*. 2021;39(11):1274-1305.

Learning Objectives:

- Apply the principles of the ASCO Guidelines to education of patients with noncastrate prostate cancer.
- Formulate a patient-specific treatment plan based on the ASCO Guidelines for men with noncastrate prostate cancer.
- Evaluate the risks and benefits of various treatment strategies used in the initial management of noncastrate prostate cancer.

#### **Breast Cancer**

Article:

Burstein HJ, Somerfield MR, Barton DL et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer: ASCO guideline update. *J Clin Oncol*. 2021;39:3959-3977.

Learning Objectives:

- Develop treatment recommendations for individual patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer based on the American Society of Clinical Oncology (ASCO) guidelines.
- Interpret results from key clinical trials in patients with HR-positive, HER2-negative metastatic breast cancer which informed the ASCO guidelines.
- Evaluate potential adverse effects and monitoring strategies for patients receiving endocrine and targeted therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.

## Colon Cancer

Article:

Meyerhardt JA, Shi Q, Fuchs C et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer. The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. *JAMA*. 2021;325(13):1277-1285.

Learning Objectives:

- Interpret the results of the CALGB/SWOG 80702 trial.
- Counsel patients or other health care providers on the utility of celecoxib in the adjuvant setting for stage III colon cancer.
- Identify the limitations of the CALGB/SWOG 80702 trial.

## Lung Cancer

Article:

Bass P, Scherpereel A, Nowak AK et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicenter, randomised, open-label, phase 3 trial. *Lancet*. 2021;397:375-386.

Learning Objectives:

- Describe the CheckMate 743 trial of nivolumab plus ipilimumab for patients with unresectable, malignant pleural mesothelioma.
- Develop recommendations for the use of nivolumab plus ipilimumab in patients with unresectable, malignant pleural mesothelioma based on the results of the CheckMate 743 trial.
- Select appropriate patients to receive nivolumab plus ipilimumab based on the results of the CheckMate 743 trial.